CPHI Podcast Series: The ripple effects of nearshoring in pharma

In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subsequent ripple effects. 

Sandra is a 35-year life sciences executive with significant operational and international experience operating top ranked pharmaceutical companies mainly in Latin America, including Pfizer, Merck, Sharp & Dohme, and Novartis, and was successful in establishing operations for Amgen and Biogen in Mexico as President and GM. 

Her entrepreneurial spirit has led her to form her own consulting firm (PharmAdvice), leveraging her extensive and in-depth experience in the commercial, regulatory, government affairs and access fields throughout Latin America. Her broad international experience has involved responsibility for regions such as Latin America, Canada, and some countries in Asia, successfully navigating through their complex changing market dynamics. She has been very successful at influencing regulatory and government environments through public policy and lobbying efforts.  

Since 2006, and in the years that follow, renowned Mexican business magazine, CNN EXPANSION, has named her one of the top 50 most powerful businesswomen in the country, and as of 2014 by Forbes Magazine. She was named by Pharma Exec’s in the USA as one of 17 Emerging Pharma Leaders in 2015. She was also one of 21 global executives selected by the International Women’s Foundation to participate in their elite Fellows Program for 2008-2010. 

Sandra has endless accolades to her name and it's incredible interesting to hear her thoughts in the following interview. Covering the wide ranging topic of nearshoring in pharma, Sandra touches on manufacturing and supply, the monopoly that some regions currently have in certain fields, the various advantages and challenges that affect both the countries and the pharma companies, as well as the impacts nearshoring has economically, through things such as trade, and importantly the social impact, in equitable access to medicine, demonstrating the real ripple effect nearshoring has. 

To listen to the full interview, follow the link below.